<DOC>
	<DOC>NCT01046799</DOC>
	<brief_summary>The purpose of this study is to determine whether hepatitis B immunoglobin can be discontinued early after hepatitis B virus (HBV) induced liver transplantation and be replaced by the nucleoside analogue entecavir to prevent hepatitis B reinfection.</brief_summary>
	<brief_title>Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>liver transplantation for hepatitis B induced endstage liver disease absence of coinfection with HIV and HCV female and male patients &gt;= 18 years of age any evidence of other causes for endstage liver disease patients that do not fulfill the criteria for liver transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>hepatitis B</keyword>
	<keyword>liver transplantation</keyword>
	<keyword>shortterm HBIg</keyword>
	<keyword>lamivudine resistance</keyword>
</DOC>